Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determinants for sustained HBeAg response to lamivudine therapy.

Hepatology (Baltimore, Md.) - 1 Nov 2003

Chien Rong-Nan, Yeh Chau-Ting, Tsai Sun-Lung, Chu Chia-Ming, Liaw Yun-Fan

Abstract excerpt

There are inconsistent data on the durability of hepatitis B e antigen (HBeAg) seroconversion after lamivudine is discontinued. The aim of this study was to examine the determinants for sustained HBeAg response to lamivudine therapy. Both host and viral factors as well as the drug factor were compared between 43 patients with sustained HBeAg response and 39 patients whose response was not sustained. All of them...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Hepatitis B, Chronic
Share to Hepatitis B e Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Lamivudine

Share to Logistic Models

Share to Recurrence

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 14578866
DOI: 10.1053/jhep.2003.50458

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determinants for sustained HBeAg response to lamivudine therapy.PMID 14578866Read ↗

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.Semantic proximity Read ↗

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.Semantic proximity Read ↗

Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factorsSemantic proximity Read ↗

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Semantic proximity Read ↗

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.Semantic proximity Read ↗

Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.Semantic proximity Read ↗

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.Semantic proximity Read ↗

Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.Semantic proximity Read ↗

Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.Semantic proximity Read ↗

Early reduction of infected hepatocytes by activated immunity at the time of interferon withdrawal hepatitis followed by lamivudine administration resulted in higher seroconversion in hepatitis Be antigen-positive patients with chronic hepatitis B.Semantic proximity Read ↗

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.